Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNLIP | P16233 | 3/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.48 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30585240 | 1.00 | PNLIP (0.50) | PNLIPPTPN1PTPN2RPS6KA5MAPKAPK2 | |
| SCHEMBL25397549 | 1.00 | PNLIP (0.50) | PNLIPPTPN1PTPN2RPS6KA5MAPKAPK2 | |
| SCHEMBL30585235 | 0.84 | ALDH1A1 (0.41) | PNLIPPTPN1PTPN2RPS6KA5MAPKAPK2 | |
| SCHEMBL31592754 | 0.84 | ALDH1A1 (0.41) | PNLIPPTPN1PTPN2RPS6KA5MAPKAPK2 | |
| SCHEMBL25433937 | 0.84 | ALDH1A1 (0.41) | PNLIPPTPN1PTPN2RPS6KA5MAPKAPK2 | |
| SCHEMBL25437972 | 0.84 | ALDH1A1 (0.41) | PNLIPPTPN1PTPN2RPS6KA5MAPKAPK2 | |
| SCHEMBL25431893 | 0.82 | PTPN1 (0.55) | PNLIPPTPN1PTPN2RPS6KA5MAPKAPK2 | |
| SCHEMBL25399107 | 0.82 | PTPN1 (0.55) | PNLIPPTPN1PTPN2RPS6KA5MAPKAPK2 | |
| SCHEMBL25395422 | 0.82 | PTPN1 (0.55) | PNLIPPTPN1PTPN2RPS6KA5MAPKAPK2 | |
| SCHEMBL15874514 | 0.82 | PTPN1 (0.55) | PNLIPPTPN1PTPN2RPS6KA5MAPKAPK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171391-A1 | PROCESS FOR PREPARING OCTAHYDRO-2(1H)-NAPHTHALENONE DERIVATIVES | FIRMENICH SA (CH) | 2025-05-29 | — | — | US | disclosed |
| EP-4479369-A1 | PROCESS FOR PREPARING OCTAHYDRO-2(1H)-NAPHTHALENONE DERIVATIVES | Firmenich SA (CH) | 2024-12-25 | — | — | EP | disclosed |
| WO-2023156429-A1 | PROCESS FOR PREPARING OCTAHYDRO-2(1H)-NAPHTHALENONE DERIVATIVES | FIRMENICH SA (CH) | 2023-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171391-A1 | PROCESS FOR PREPARING OCTAHYDRO-2(1H)-NAPHTHALENONE DERIVATIVES | POR, NDUFV1, NDUFV2 | PNLIP 1966/4885PTPN1 4332/4885PTPN2 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.